Mexico City, May 14 (EFE) .- The Government of Mexico City reported this Friday that according to a study in which it analyzed the use of ivermectin in people positive for covid-19, it identified a reduction of between 52 and 76% the probability of being hospitalized.
At a press conference, the mayor of the capital, Claudia Sheinbaum, explained that in January of this year a medical group from the Mexican Institute of Social Security (IMSS) and the Ministry of Health of the capital met with national and international medical specialists who administered ivermectin and acetylsalicylic acid.
And after detecting that there were practically “no side effects, it was decided to include said drugs in the medical kit” that the capital government granted to positive patients, in addition to providing specialized medical monitoring.
Meanwhile, the head of the Digital Public Innovation Agency of the capital, José Merino, explained that through more than 220,000 observations in people, a reduction in the probability of being hospitalized of between 52 and 76% was detected for people who received the kit with the medicines.
Regarding the use of the drug, on March 31, the World Health Organization (WHO) recommended not to use ivermectin in patients suffering from covid-19, regardless of the severity of the symptoms they develop and their duration.
The WHO stated in a guide on therapies against covid-19, published that date, that ivermectin should only be used in the context of clinical trials.
Ivermectin is a low-cost drug against parasites that is used in many countries, especially in Latin America, in people infected with the coronavirus, despite the fact that its efficacy for this disease has not been validated by medical studies.
“The recommendation to use a drug only in the context of a clinical trial is appropriate when there is little evidence to provide certainty,” explained the Organization.
The Government of the Mexican capital also announced that they will soon report on the results of the study carried out by the city’s Ministry of Health with the application of the drug Remdesivir to hospitalized patients in Mexico City, which show an incidence in the decrease of the mortality.
(c) EFE Agency